Specialty Pharmacy

Consuming 2.5 servings of coffee per day found to decrease colorectal cancer development by up to 50%.

Some genetic variants have the potential to affect responses to immunosuppressive drugs that influence organ rejection.

Top news of the day from across the health care landscape.

New technique offers sustained release of antibodies directly to skin cancer tumor.

Afatinib (Gilotrif) shows significant improvements in overall survival and disease progression.

Patients put themselves at risk by not reading active ingredient listings on drug packaging.

Optic neuropathy is common in multiple sclerosis as the immune system destroys myelin and damages the nerves.

Recent advances and updates in oncology and cancer drug development.

HCV-related deaths continued to rise while deaths from 60 other infectious diseases declined.

Prescription drugs, over-the-counter drugs, and dietary supplements lead to potentially deadly combinations.

Sulindac and erlotinib effectively reduced the total duodenal polyps in patients with familial adenomatous polyposis.

Novel drug RG-101 could shorten the treatment time for hepatitis C virus (HCV) infection to 4 weeks.

Zepatier achieves sustained virologic response rate of 99.2% during a 12 to 16 week treatment course in patients with HCV.

Directories include lists of clinicians, providers, and health care facilities within health plan networks.

Helping patients navigate manufacturer prescription assistance programs found to lower hospitalization costs.

Sugary drinks found to triple the risk of developing prostate cancer.

Top news of the week on Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Dietary intake of methionine and tryptophan may slow brain cancer tumor progression.

Single-cell method identifies core stem cells that cause leukemia within a tumor.

Pharmacists can aggressively intervene to adjust medications when patients’ diabetes is uncontrolled.

Higher consumer out-of-pocket costs could be a barrier to patient adoption of biosimilar drugs.

Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells in MS patients.

HCV testing rises in substance use disorder treatment programs.

Injections of new formulation of raltegravir may only be needed every month.

Ruptured cancerous cells are able to repair themselves to prevent cell death.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Top news of the day from across the health care landscape.